1. Home
  2. FC vs CABA Comparison

FC vs CABA Comparison

Compare FC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FC
  • CABA
  • Stock Information
  • Founded
  • FC 1983
  • CABA 2017
  • Country
  • FC United States
  • CABA United States
  • Employees
  • FC N/A
  • CABA N/A
  • Industry
  • FC Other Consumer Services
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FC Consumer Discretionary
  • CABA Health Care
  • Exchange
  • FC Nasdaq
  • CABA Nasdaq
  • Market Cap
  • FC 236.1M
  • CABA 260.7M
  • IPO Year
  • FC 1992
  • CABA 2019
  • Fundamental
  • Price
  • FC $15.11
  • CABA $2.40
  • Analyst Decision
  • FC Strong Buy
  • CABA Strong Buy
  • Analyst Count
  • FC 2
  • CABA 8
  • Target Price
  • FC $24.50
  • CABA $13.50
  • AVG Volume (30 Days)
  • FC 98.0K
  • CABA 5.9M
  • Earning Date
  • FC 11-05-2025
  • CABA 11-07-2025
  • Dividend Yield
  • FC N/A
  • CABA N/A
  • EPS Growth
  • FC N/A
  • CABA N/A
  • EPS
  • FC 0.24
  • CABA N/A
  • Revenue
  • FC $267,067,000.00
  • CABA N/A
  • Revenue This Year
  • FC $4.21
  • CABA N/A
  • Revenue Next Year
  • FC $44.35
  • CABA N/A
  • P/E Ratio
  • FC $66.99
  • CABA N/A
  • Revenue Growth
  • FC N/A
  • CABA N/A
  • 52 Week Low
  • FC $15.41
  • CABA $0.99
  • 52 Week High
  • FC $44.16
  • CABA $5.46
  • Technical
  • Relative Strength Index (RSI)
  • FC 33.01
  • CABA 46.16
  • Support Level
  • FC $16.29
  • CABA $2.39
  • Resistance Level
  • FC $17.86
  • CABA $3.67
  • Average True Range (ATR)
  • FC 0.95
  • CABA 0.34
  • MACD
  • FC -0.19
  • CABA -0.06
  • Stochastic Oscillator
  • FC 3.62
  • CABA 4.74

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: